Amgen dips after trial update for Zai Lab partnered gastric cancer therapy


Cancer cell view

Amgen (NASDAQ:AMGN) stock dipped on Wednesday following an update from its partner, Zai Lab (NASDAQ:ZLAB), regarding the late-stage trial of bemarituzumab combined with chemotherapy for gastric cancer treatment.

The interim analysis of the trial, which focused on first-line gastric cancer treatment, revealed



Source link

Photography practice: Take what you can get

Jennifer Aniston Talks Brangelina, Scandal That Broke the Internet

Leave a Reply

Your email address will not be published. Required fields are marked *